# **Product** Data Sheet

## KKI-5 TFA

Cat. No.: HY-P0237A Molecular Formula:  $C_{37}H_{56}F_3N_{11}O_{11}$ 

Molecular Weight: 887.9

Sequence: Ac-Pro-Phe-Arg-Ser-Val-Gln-NH2

Sequence Shortening: Ac-PFRSVQ-NH2

Target: Others Pathway: Others

Storage: Sealed storage, away from moisture

> Powder -80°C 2 years -20°C 1 year

\* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

### **SOLVENT & SOLUBILITY**

In Vitro

H<sub>2</sub>O: 9.09 mg/mL (10.24 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.1263 mL	5.6313 mL	11.2625 mL
	5 mM	0.2253 mL	1.1263 mL	2.2525 mL
	10 mM	0.1126 mL	0.5631 mL	1.1263 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: PBS

Solubility: 12.5 mg/mL (14.08 mM); Clear solution; Need ultrasonic

### **BIOLOGICAL ACTIVITY**

Description	KKI-5 (TFA) is a specific inhibitor of tissue kallikrein. KKI-5 (TFA) can attenuate breast cancer cell invasion $^{[1]}$ .		
IC <sub>50</sub> & Target	Kallikrein <sup>[1]</sup>		
In Vitro	The KKI-5 Peptide corresponds to aa386-391 of bovine kininogen-1 that encompasses the aa388-389 kallikrein proteolytic site. The synthetic KKI-5 can attenuate breast cancer cell invasion, therefore it is investigated for its role in invasion and metastasis of cancer cells <sup>[1]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only.		

#### **REFERENCES**



Page 2 of 2 www.MedChemExpress.com